Free Trial

Longeveron (LGVN) Stock Price, News & Analysis

-0.04 (-3.14%)
(As of 05/20/2024 ET)
Today's Range
50-Day Range
52-Week Range
343,945 shs
Average Volume
1.43 million shs
Market Capitalization
$3.10 million
P/E Ratio
Dividend Yield
Price Target

Longeveron MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
871.7% Upside
$12.00 Price Target
Short Interest
3.56% of Float Sold Short
Dividend Strength
News Sentiment
0.78mentions of Longeveron in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$350,000 Bought Last Quarter
Proj. Earnings Growth
From ($6.77) to ($5.07) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.80 out of 5 stars

LGVN stock logo

About Longeveron Stock (NASDAQ:LGVN)

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.

LGVN Stock Price History

LGVN Stock News Headlines

Longeveron (NASDAQ:LGVN) Rating Reiterated by HC Wainwright
Longeveron Inc. (LGVN)
Longeveron to Present at the Planet MicroCap Showcase
What's Going On With Longeveron Stock?
Why Is Longeveron (LGVN) Stock Up 48% Today?
Why Is Longeveron (LGVN) Stock Up 48% Today?
Why Is Longeveron (LGVN) Stock Up 82% Today?
Longeveron Announces 1-for-10 Reverse Stock Split
See More Headlines
Receive LGVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Longeveron and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$2.68 per share


Free Float
Market Cap
$3.11 million
Not Optionable
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Joshua Michael Hare FACC (Age 61)
    M.D., Co-Founder, Chief Science Officer & Chairman
    Comp: $74k
  • Mr. Mohamed Wa'el Ahmed Hashad (Age 62)
    CEO & Director
    Comp: $781.56k
  • Ms. Lisa A. Locklear M.B.A. (Age 62)
    Executive VP & CFO
    Comp: $248.38k
  • Mr. Paul T. Lehr J.D.Mr. Paul T. Lehr J.D. (Age 56)
    International Executive Director, General Counsel & Secretary
    Comp: $554.05k
  • Dr. Dan Gincel Ph.D. (Age 53)
    Senior Vice President of Strategic Collaborations & Scientific Affairs
  • Dr. Nataliya Agafanova M.D. (Age 54)
    Chief Medical Officer
  • Ms. Elly Ryu (Age 42)
    VP & Corporate Controller

LGVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Longeveron stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Longeveron in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LGVN shares.
View LGVN analyst ratings
or view top-rated stocks.

What is Longeveron's stock price target for 2024?

1 Wall Street analysts have issued 1 year price objectives for Longeveron's stock. Their LGVN share price targets range from $12.00 to $12.00. On average, they anticipate the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 871.7% from the stock's current price.
View analysts price targets for LGVN
or view top-rated stocks among Wall Street analysts.

How have LGVN shares performed in 2024?

Longeveron's stock was trading at $13.60 at the beginning of 2024. Since then, LGVN stock has decreased by 90.9% and is now trading at $1.2350.
View the best growth stocks for 2024 here

When is Longeveron's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024.
View our LGVN earnings forecast

How were Longeveron's earnings last quarter?

Longeveron Inc. (NASDAQ:LGVN) issued its quarterly earnings results on Tuesday, May, 14th. The company reported ($1.61) earnings per share for the quarter, beating analysts' consensus estimates of ($2.01) by $0.40. The firm had revenue of $0.55 million for the quarter, compared to analyst estimates of $0.12 million. Longeveron had a negative trailing twelve-month return on equity of 300.96% and a negative net margin of 2,129.24%. During the same period last year, the business earned ($2.20) EPS.

When did Longeveron's stock split?

Shares of Longeveron reverse split on Wednesday, March 27th 2024. The 1-10 reverse split was announced on Wednesday, March 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Longeveron IPO?

Longeveron (LGVN) raised $30 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 2,700,000 shares at $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. served as the underwriters for the IPO.

How do I buy shares of Longeveron?

Shares of LGVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LGVN) was last updated on 5/20/2024 by Staff

From Our Partners